Naples, Royal Continental Hotel
December 3rd - 6th, 2014
ORGANIZED BY

Fondazione Melanoma Onlus

National Cancer Institute “Fondazione G. Pascale”

Sidra Medical and Research Center

Society for Immunotherapy of Cancer

UNDER THE AUSPICES OF

Associazione Italiana di Oncologia Medica

European Society for Medical Oncology
GENERAL INFORMATION

CME PROVIDER AND ORGANISING AGENCY:
3P Solution Srl
Via Marradi 3, 20123 Milan
Phone +39 02 36631574 | Fax +39 02 36631640
Cell. +39 3496485434
www.3psolution.it
info@3psolution.it
info@melanomabridge.org

OFFICIAL LANGUAGE:
The official language is English

REGISTRATION:
Only registered attendees will be admitted to the meeting.
The registration fee includes:
- participation in the scientific program
- CME credits
- coffee breaks and lunches from December 3rd to 6th
- congress bag

Participants are kindly requested to inform us about any dietary habit (i.e. food allergies/intolerances, vegetarian or vegan habits).

Please register at 3P Solution desk (cash or credit card accepted).

CONGRESS VENUE:
Royal Continental Hotel
Via Partenope, 38-44
80121 - Naples
Phone +39 081 245 2068
www.royalgroup.it/royalcontinental/
CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Provider (code 327) and has a quality-management system that meets the requirements of UNI EN ISO 9001:2008, with CSQA certificate no. 23887.

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Melanoma Bridge 2014 has been accredited with 8.5 CME credits for 200 participants of the following professions: Medical Doctors, Pharmacists, Biologists, and Nurses.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

In order to receive credits, participants must:
1. Attend all the accredited sessions;
2. Complete the assessment test at the end of the congress (a grade of 75% must be obtained to receive CME credit);
3. Complete the evaluation questions at the end of the congress.

CME certificate attendance will be sent to the participants at the end of the evaluation procedure.

MY ECM

Age.na.s has activated the service MyEcm (personalized page available to any health professional), which enables you to:
1. Consult the CME events offer
2. Refer to the summary of events attended and credits earned
3. Provide an assessment of courses organized by the Provider

To access online services please log on to http://ape.agenas.it/professionisti/myecm.
If this meeting fulfilled your expectations, please click on 👍 and give your assessment.

ESMO-MORA ACCREDITATION:

Melanoma Bridge 2014 is accredited by ESMO for 22, category 1 ESMO-MORA points
SCIENTIFIC PROGRAM
December 3rd, 2014

OPENING CEREMONY **
Chair: Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo

17:00 Welcome and introduction
Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo

17:30 Award lecture of Fondazione Melanoma:
Melanoma vaccines: New targets and combination therapy
Giorgio Parmiani

18:00 Clinical trial and real world evidence
Paul Lorigan

18:30 Patients meet the melanoma experts

A pan-European policy strategy to overcome inequalities:
Impact on Melanoma
Francesco De Lorenzo (European Cancer Patient Coalition)

The Challenges Ahead for Patient Advocacy
Valerie Guild (AIM at Melanoma)

Patient-centered clinical research in Melanoma
Bettina Ryll (Melanoma Patient Network Europe)

Representatives of Fondazione Melanoma Onlus
Antonio Brancaccio, Elisabetta Colangelo

Roundtable

Simultaneous translation will be provided.
È prevista la traduzione simultanea

**Not included in the CME accredited program
MOLECULAR AND IMMUNO ADVANCES

Chair: Gerardo Botti, Ena Wang

09:30 Genetic evolution of melanocytic neoplasia
Boris C. Bastian

09:55 The multi-faced roles of the PI3K-AKT pathway in melanoma
Michael Davies

10:20 Evolution of resistance to MAPK-targeted therapies
Roger Lo

10:45 ErbB3 as a key factor in the development of resistance
to RAF/MEK inhibitors in BRAF mutated melanoma
Gennaro Ciliberto

11:10 Break

11:25 Tumor Infiltrating Lymphocytes (TIL’s) Rule in
Melanoma Prognosis
Martin Mihm

11:50 Molecular enhancement of sentinel node evaluation
Alistair Cochran

12:15 Mechanisms of synergy of radiotherapy and immunotherapy
Sandra Demaria

12:40 Discussion on the best abstracts submitted on Molecular
and Immuno advances
Gerardo Botti, Ena Wang
SCIENTIFIC PROGRAM

December 4th, 2014

Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells
Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, Giulia Mesiano, Michela Cangemi, Alessandro Zaccagna, Alberto Pisacane, Susanna Gallo, Fabrizio Carnevale-Schianca, Massimo Aglietta, Dario Sangiolo

RSK1 activation promotes invasion in nodular melanoma
Amel Salhi, Joshua A. Farhadian, Keith M. Giles, Eleazar Vega-Saenz de Miera, Ines P. Silva, Caitlin Bourque, Karen Yeh, Sagar Chhangawala, Jinhua Wang, Fei Ye, David Y. Zhang, Eva Hernando, Yariv Houvras, Iman Osman

10:00 Launch of the Patients and Clinicians Italian Working Group on Melanoma**

Roundtable
Paolo A. Ascierto, Antonio Brancaccio, Alberto Cerretti, Elisabetta Colangelo, Francesco De Lorenzo, Valerie Guild, Nicola Mozzillo, Chiara Puri Purini, Paola Queirolo, Carlo Riccardo Rossi, Alessandro Testori, Sara Vigna

SALA CAPUANA

13:30 Lunch and Poster Session

**Not included in the CME accredited program
COMBINATION THERAPIES

Chair: Paolo A. Ascierto, Giuseppe Palmieri

14:30  Beyond BRAFi/MEK/i: Combination and sequencing approaches for patients with BRAF mutant melanoma
       Michael Atkins

14:55  Novel combination therapies for BRAF-mutant melanoma
       Grant McArthur

15:20  MEK + CDK4 a regimen for non-BRAF V600E melanoma
       Jeff Sosman

15:45  Combining targeted drugs and immunotherapy for melanoma
       Igor Puzanov

16:10  Break

16:25  Combination therapies based on PD-1/PDL-1 pathway antagonists
       Mario Sznol

16:50  Strategies and designs for combination immune therapy
       Samir Khleif

17:15  Combining radiation therapy with immunotherapy: clinical translation
       Silvia Formenti

17:40  Surgery in the combination therapies era
       Nicola Mozzillo
18:05 Discussion on the best abstracts submitted on Combination Therapies
Paolo A. Ascierto, Giuseppe Palmieri

Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma
Adil Daud, Kathryn Toshimi Takamura, Tu Diep, Richard Heller, Robert H. Pierce

cobRIM: A Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated BRAF V600 Mutation–Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (NCT01689519)
Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandala, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Ilsung Chang, Stephen P. Hack, Antoni Ribas

18:35 Closing remarks and summing up for the next day
Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo
NEWS IN IMMUNOTHERAPY
Chair: Claus Garbe, Alessandro Testori

09:20  Adjuvant therapy of melanoma in 2014
   John Kirkwood

09:45  Grp94-specific monoclonal antibody to counteract
   BRAF inhibitor resistance in BRAF<sup>V600E</sup> melanoma
   Soldano Ferrone

10:10  Myeloid derived suppressor cells in malignant melanoma
   are inhibitors of adaptive and innate immunity
   Rolf Kiessling

10:35  Targeting multiple inhibitory receptors to reverse
   melanoma-induced T cell dysfunction
   Hassane M. Zarour

11:00  Break

11:20  Role of signal transduction and microRNAs on
   the immunogenicity of melanoma cells
   Barbara Seliger

11:45  Advances in adoptive cellular therapy of cancer
   David Stroncek

12:35  Discussion on the best abstracts submitted on News
   in immunotherapy
   Claus Garbe, Alessandro Testori
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma


Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma


Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients

Yago Pico de Coaña, Maria Wolodarski, Giusy Gentilcore, Yuya Yoshimoto, Isabel Poschke, Johan Hansson, Giuseppe V. Masucci, Rolf Kiessling
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients

Rossana Tallerico, Costanza M. Cristiani, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Ester Simeone, Andrea Dominijanni, Antonio M. Grimaldi, Francesco Colucci, Paolo A. Ascierto, Ennio Carbone

13:20 Lunch and Poster Session

TUMOR MICROENVIRONMENT AND BIOMARKERS
Chair: Giuseppe Masucci, Magdalena Thurin

14:30 Genetic heterogeneity and transcriptional plasticity drive resistance during immunotherapy and targeted therapy
Reinard Dummer

14:55 The immune-related role of BRAF in melanoma
Sara Tomei

15:20 T cell responses to melanoma antigens
Pedro Romero

15:45 Molecular and cellular basis for immunomodulation with monoclonal antibodies
Ignacio Melero

16:10 Break

16:25 PD-LS and PD-1 as predictive markers of response to anti-PD-1
Janis Taube
16:50 Re-activation of T cells within the tumor microenvironment
Thomas F. Gajewski

17:15 Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
Bastian Schilling

17:40 Discussion on the best abstracts submitted on Tumor Microenvironment and Biomarkers
Giuseppe Masucci, Magdalena Thurin

Tumor-infiltrating lymphocytes predict cutaneous melanoma survival
Cristina Fortes, Simona Mastroeni, Thomas Manooran paranpampil, Francesca Passarelli, Alba Zappalà, Claudia Marino, Nicoletta Russo, Paola Michelozzi

αβ-Double Negative CD4/CD8 (CD56) T cell (DNTs) as prognostic markers in metastatic melanoma patients treated with Ipilimumab: preliminary evaluations
Giacoma De Tullio, Sabino Strippoli, Rosa Angarano, Vincenza De Fazio, Nicola Sgherza, Antonio Negri, Anna Albano, Pasquale Iacopino, Attilio Guarini, Michele Guida

Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)
Adil Daud, Alain Algazi, Michelle Ashworth, Michael Buljan, Kathryn Toshimi Takamura, Tu Diep, Robert H. Pierce, Shailender Bhatia

18:30 Closing remarks and summing up for the next day
Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo
WORLD-WIDE IMMUNOSCORE TASK FORCE: AN UPDATE**
Chair: Paolo A. Ascierto, Jerome Galon, Francesco M. Marincola

08:30 Immunoscore participants round table on recent advances

The Worldwide Immunoscore consortium in the era of tumor immunotherapies
Jerome Galon

Immunoscore in melanoma
Paolo A. Ascierto

SITC Immunoscore cloud hosting and an update on the Portland cohort
Carlo Bifulco

Quantitative Pathology for the discovery of immunoncological biomarkers
sponsored by Definiens
Ralf Huss

Immunoscore and immunoprofiling in clinical trials
Magdalena Thurin

The implementation of the immunoscore in the daily diagnostic practice of colorectal cancer: the pathologist’s point of view
Alessandro Lugli

The contribution of Karolinska Institute to the immunoscore task force
Giuseppe Masucci

**Not included in the CME accredited program
SCIENTIFIC PROGRAM

December 6th, 2014

Qatar Immunoscore update-Breast Cancer Immunoscore Pilot Project
Shahinaz Bedri

10:30 Discussion
Boris C. Bastian
Gerardo Botti
Sandra Demaria
Reinard Dummer
Thomas F. Gajewski
Martin Mihm
Janis Taube
Magdalena Thurin

11:15 Break

REGULATORY SESSION
Chair: Paolo A. Ascierto, Pier Luigi Canonico

11:30 Roundtable on the economic sustainability of the new melanoma treatments: regulatory and market access issues

11:30 Melanoma: the development of a multiprofessional discussion
Alessandro Testori

11:45 Regulatory Updates for Cancer Vaccines, Cellular and Gene Therapy Products
Raj Puri

12:00 The point of view of EMA
Francesco Pignatti
12:15  The point of view of AIFA
Paolo Foggi*

12:30  Expanded Access Program and Compassionate Use
Paul Lorigan

12:45  Economic evaluation of new drugs and its role in managing their market access
Claudio Jommi

13:00  Discussion
Francesco De Lorenzo
Teresita Mazzei
Francesco Rossi

13:30  CME test

*To be confirmed
MOLECULAR AND IMMUNO ADVANCES

1. Case report: CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance
   Maurizio Governa, Evelina Caprarella, Edoardo Dalla Pozza, Enrico Vigato, Monia Maritan, Marina Zannoni, Paolo Rosina, Camilla Stagni, Lisa Elefanti, Chiara Menin

2. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
   Emilia Caputo, Roberta Miceli, Maria L. Motti, Rosarita Taté, Federica Fratangelo, Gerardo Botti, Nicola Mozzillo, Maria V Carriero, Ernesta Cavalcanti, Giuseppe Palmieri, Gennaro Ciliberto, Giuseppe Pirozzi, Paolo A Ascierto

3. Exome sequencing in primary melanoma identifies novel drivers of melanoma progression
   Valentina Montagnani, Matteo Benelli, Alessandro Apollo, Silvia Pandolfi, Gianni Gerlini, Lorenzo Borgogno, Barbara Stecca

4. The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
   Letizia Porcelli, Gabriella Guida, Tiziana Cocco, Anna E. Quatrale, Rosa M Iacobazzi, Diana A Stolfa, Imma Maida, Anna Ferretta, Claudia Greco, Stefania Guida, Sabino Strippoli, Stefania Tommasi, Michele Guida, Amalia Azzariti

5. microRNAs and next generation sequencing for the prognosis of the metastatic melanoma
   Rosamaria Pinto, Simona De Summa, Sabino Strippoli, Gabriella Guida, Ondina Popescu, Amalia Azzariti, Michele Guida, Stefania Tommasi
6. Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-kB or the PI3K/mTOR signalling pathway
**Simona Caporali, Ester Alvino, Adriana Amaro, Pedro Lacal, Lauretta Levati, Maria Grazia Atzori, Gian Carlo Antonini Cappellini, Federica Ruffini, Enzo Bonmassar, Ulrich Pfeffer, Stefania D’Atri**

7. Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
**Federica Ruffini, Grazia Graziani, Lauretta Levati, Lucio Tentori, Simona Caporali, Stefania D’Atri, Pedro M Lacal**

**COMBINATION THERAPIES**
8. Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
**Andrea P Sponghini, David Rondonotti, Marco Giavarra, Roberto Giorgione, Francesca Platini**

**Sara Giovannoni, Federica Urbano, Daniela Modica, Sofia Verkhovskaiia, Giuliana Caprio, Silvia Mezi, Enrico Cortesi**
POSTER SESSION

TUMOR MICROENVIRONMENT AND BIOMARKERS

10. Simultaneous determination of two serum tumor markers in assessing malignant melanoma patients
   Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca, Alexandru Blidaru

11. Clinical value of Melanoma Inhibitory Activity in stratifying malignant melanoma patients
   Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca, Alexandru Blidaru

12. Melanoma Inhibitory Activity and regional lymph node status in malignant melanoma patients
   Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca, Alexandru Blidaru

13. Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients
   Angela Vasaturo, Dagmar Verweij, Lucie Heinzerling, Willeke Blokx, Carl G Figdor

14. Gender differences and outcome of melanoma patients
   Francesca Morgese, Rossana Berardi, Caterina Sampaolesi, Mariangela Torniai, Giulia Marcantognini, Alfredo Giacchetti, Stefano Serresi, Azzurra Onofri, Alessandro Bittoni, Alberto Pilone, Giuseppe Ricotti, Stefano Cascinu

15. Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker
   Stucci Stefania, Tucci Marco, Passarelli Anna, Mannavola Francesco, Felici Claudia, Giudice Giuseppe, Silvestris Franco
16. Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. 

Stucci Stefania, Tucci Marco, Ascierto Paolo Antonio, Passarelli Anna, Capone Mariaelena, Madonna Gabriele, Simeone Ester, Grimaldi Antonio Maria, Silvestris Franco

17. “Immune B Cells known it better”: tumorimmunological panel assay to define tumor-associated antigen binding antibodies in patients with metastatic melanomas 

Beatrix Kotlan, Timea Balatoni, Katalin Csirbesz, Judit Olasz, Orsolya Csuka, Laszlo Toth, Emil Farkas, Akos Savolt, Andras Szollar, Mihaly Ujhelyi, Szabolcs Horvath, Klara Eles, Miklos Kasler, Francesco M Marincola, Gabriella Liszkay
PRESIDENCY

Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Francesco M. Marincola
Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Nicola Mozzillo
Director of the Department of Surgical Oncology B, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

SCIENTIFIC BOARD

Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Gennaro Ciliberto
Scientific Director of the National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Claus Garbe
University Professor of Dermatology, Head, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany
SCIENTIFIC BOARD

John M. Kirkwood
Professor of Medicine, Dermatology and Translational Science, Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute, Pennsylvania

Francesco M. Marincola
Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci
Professor, Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Ignacio Melero
Professor of Immunology and Consultant, CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

Nicola Mozzillo
Director of the Department of Surgical Oncology B, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Giuseppe Palmieri
Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

Alessandro Testori
Director of the Dermato-oncology Surgery Division, European Institute of Oncology, Milan, Italy

Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland
FACULTY

Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Michael Atkins
Georgetown-Lombardi Comprehensive Cancer Center in Washington, DC

Boris C. Bastian
Departments of Dermatology and Pathology, University of California, San Francisco, California

Carlo Bifulco
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Gerardo Botti
National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Pier Luigi Canonico
Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy

Lotfi Chouchane
Weill Cornell Medical College, Qatar

Gennaro Ciliberto
National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Alistair Cochran
Ronald Reagan UCLA Medical Center, UCLA, California

Michael Davies
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Francesco De Lorenzo
President of European Cancer Patient Coalition, ECPC, and of Italian Federation of Volunteer-based Cancer Organizations, FAVO

Sandra Demaria
New York University Langone Medical Center, New York
FACULTY

Reinhard Dummer
University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Soldano Ferrone
Massachusetts General Hospital, Boston, Massachusetts

Paolo Foggi*
Italian Medicines Agency, AIFA

Silvia Formenti
New York University Langone Medical Center, New York

Thomas F. Gajewski
Department of Pathology and Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois

Jerome Galon
INSEIR (National Institute of Health and Medical Research), Paris, France

Claus Garbe
Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

Valerie Guild
AIM at Melanoma, Richmond, California

Claudio Jommi
Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy

Rolf Kiessling
Karolinska Institutet, Stockholm, Sweden

John M. Kirkwood
Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute, Pennsylvania

Samir Khleif
Georgia Regents University Cancer Center, Augusta, Georgia
FACULTY

Roger Lo
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California

Paul Lorigan
Institute of Cancer Sciences, University of Manchester, Manchester, UK

Alessandro Lugli
Institute of Pathology, University of Bern, Bern, Switzerland

Francesco M. Marincola
Chief Research Officer, Sidra Medical and Research Center, Doha, Qatar

Giuseppe Masucci
Karolinska Institutet, Stockholm, Sweden

Teresita Mazzei
Department of Health Sciences, University of Florence, Florence, Italy

Grant McArthur
Peter MacCallum Cancer Centre, Melbourne Area, Australia

Ignacio Melero
CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

Martin Mihm
Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Nicola Mozzillo
Department Melanoma and Soft Tissues, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Giuseppe Palmieri
Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

Giorgio Parmiani
Division of Medical Oncology and Immunotherapy, University Hospital, Siena
Francesco Pignatti  
Onkology, Haematology, Diagnostics - Safety and Efficacy Sector at European Medicines Agency, EMA

Carmine Pinto  
President of the Italian Association of Medical Oncology, AIOM

Raj K. Puri  
Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research FDA, Bethesda, Maryland

Igor Puzanov  
Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee

Paola Queirolo  
President of the Italian Melanoma Intergroup, IMI

Pedro Romero  
Ludwig Center for Cancer Research, University of Lausanne, Switzerland

Francesco Rossi  
President of the Italian Society of Pharmacology, SIF

Bettina Ryll  
Melanoma Patient Network Europe

Bastian Schilling  
Department of Dermatology, University Hospital Essen, Essen, Germany

Barbara Seliger  
Institute of Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle, Saale, Germany

Jeff Sosman  
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

David Stroncek  
Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland
Naples, Royal Continental Hotel  
December 3rd - 6th, 2014  

FACULTY  

Mario Sznol  
Yale Cancer Center, New Haven, Connecticut  

Janis M. Taube  
Departments of Dermatology and Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland  

Alessandro Testori  
Director of the Dermato-oncology Surgery Division, European Institute of Oncology, Milan, Italy  

Magdalena Thurin  
Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland  

Sara Tomei  
Sidra Medical and Research Centre, Doha, Qatar  

Ena Wang  
Sidra Medical and Research Centre, Doha, Qatar  

Hassane M. Zarour  
University of Pittsburgh Cancer Institute Hillman Cancer Center, Pennsylvania
Melanoma Bridge 2014 is sponsored by an *unrestricted grant* from:

**PLATINUM SPONSOR**

Bristol-Myers Squibb

**SILVER SPONSOR**

Roche, MSD

**SPONSOR**

Novartis, MedImmune, gsk, IGEA, MerckSerono, MERCK, DEFINIENS, AMGEN, Biocartis